

10. The composition of Claim 7, wherein said pharmaceutical carrier is a gel.

11. The composition of Claim 7, wherein said extract is included in said pharmaceutical carrier in an amount effective to reduce the symptoms of psoriasis.

12. The composition of Claim 7, wherein said extract comprises effective amounts of 3-methylanthralin, chrysophanol, aloe-emodin, and aloe-emodin acetate.

13. A method for treating psoriasis comprising ✓

a) providing:

i) a composition comprising an extract from *Asphodelus microcarpus* and a pharmaceutical carrier for topical administration; and

ii) a patient having symptoms psoriasis; and

b) topically applying said composition to said patient under conditions such that said symptoms of psoriasis are reduced.

14. The method of Claim 13, wherein said pharmaceutical carrier is selected from the group consisting of liquids, gels, sprays, creams, and dermal patches.

15. The method of Claim 13, wherein said pharmaceutical carrier is a cream.

16. The method of Claim 13, wherein said pharmaceutical carrier is a gel.

17. The method of Claim 13, wherein said extract is included in said pharmaceutical carrier in an amount effective to reduce the symptoms of psoriasis.

18. The method of Claim 13, wherein said extract comprises effective amounts of 3-methylanthralin, chrysophanol, aloe-emodin, and aloe-emodin acetate.

19. A method for preparing a pharmaceutical preparation comprising: ✓

a) providing:

- i) an extract from *Asphodelus microcarpus*; and
- ii) a pharmaceutical carrier for topical administration; and
- b) preparing a pharmaceutical preparation from said extract and said pharmaceutical carrier.

20. The method of Claim 19, wherein said pharmaceutical carrier is selected from the group consisting of liquids, gels, sprays, creams, and dermal patches.

21. The method of Claim 19, wherein said pharmaceutical carrier is a cream.

22. The method of Claim 19, wherein said pharmaceutical carrier is a gel.

23. The method of Claim 19, wherein said extract is included in said pharmaceutical carrier in an amount effective to reduce the symptoms of psoriasis.

24. The method of Claim 19, wherein said extract comprises effective amounts of 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin acetate.

25. A pharmaceutical preparation prepared according to Claim 19.

26. A composition comprising an effective amount of purified aloe-emodin monoacetate in a pharmaceutical carrier.

27. The composition of Claim 26, wherein said effective amount is an amount sufficient to relieve the symptoms of psoriasis in a patient.

28. The composition of Claim 26, further comprising at least one compound selected from the group consisting of 3-methylantralin, chrysophanol, and aloe-emodin.

29. The composition of Claim 26, wherein said composition further comprises 3-methylantralin and chrysophanol.

30. The composition of Claim 26, wherein said pharmaceutical carrier is selected from the group consisting of pills, tablets, capsules, liquids, gels, sprays, creams, dermal patches, and suppositories.

31. The composition of Claim 26, wherein said pharmaceutical carrier is a cream.

32. The composition of Claim 26, wherein said pharmaceutical carrier is a gel.

33. A composition comprising a cream including an effective amount of aloe-emodin monoacetate. ✓

34. A composition comprising a gel including an effective amount of aloe-emodin monoacetate. ✓

35. A method for preparing a pharmaceutical preparation comprising: ✓

- a) providing purified aloe-emodin monoacetate; and
- b) formulating said pharmaceutical preparation, wherein said pharmaceutical preparation comprises an effective amount of said substantially purified aloe-emodin monoacetate.

36. The method of Claim 35, wherein said effective amount is an amount sufficient to relieve the symptoms of psoriasis in a patient.

37. The method of Claim 35, further comprising providing at least one compound selected from the group consisting of 3-methylantralin, chrysophanol, and aloe-emodin and combining said at least one compound with said aloe-emodin monoacetate to provide said preparation.

38. The method of Claim 35, wherein said pharmaceutical carrier is selected from the group consisting of pills, tablets, capsules, liquids, gels, sprays, creams, dermal patches, and suppositories.

39. The method of Claim 35, wherein said pharmaceutical carrier is a cream.

40. The method of Claim 35, wherein said pharmaceutical carrier is a gel.

41. A method for preparing a pharmaceutical preparation comprising: ✓

a) providing purified aloe-emodin monoacetate and at least one compound selected from the group consisting of 3-methylanthralin, chrysophanol, and aloe-emodin; and  
b) formulating said pharmaceutical preparation, wherein said pharmaceutical preparation comprises an effective amount of said purified aloe-emodin monoacetate and said at least one compound selected from the group consisting of 3-methylanthralin, chrysophanol, and aloe-emodin.

42. The method of Claim 41, wherein said effective amount is an amount sufficient to relieve the symptoms of psoriasis in a patient.

43. The method of Claim 41, wherein said pharmaceutical preparation is selected from the group consisting of pills, tablets, capsules, liquids, gels, sprays, creams, dermal patches, and suppositories.

44. A method for preparing a pharmaceutical gel or cream comprising: ✓

a) providing purified aloe-emodin monoacetate; and  
b) preparing a pharmaceutical gel or cream comprising an effective amount of said aloe-emodin monoacetate.

45. The method of Claim 44, further comprising providing at least one compound selected from the group consisting of 3-methylanthralin, chrysophanol, and aloe-emodin and combining said at least one compound with said aloe-emodin monoacetate to provide said preparation.

46. A method for inhibiting keratinocyte proliferation comprising: ✓

a) providing